NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

SNTI

Senti Biosciences Inc

Jul 14 • 04:00PM ET

1.97

Dollar change -0.16
Percentage change -7.51	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP BEAM EDIT IOVA NTLA GILD BLUE FATE SGMO NRIX

| Held by: VTI VXF IWC DFAC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-10.84	Insider Own	69.44%	Shs Outstand	26.00M	Perf Week	-10.86%
Market Cap	51.38M	Forward P/E	-	EPS next Y	-2.13	Insider Trans	-0.03%	Shs Float	7.97M	Perf Month	-29.89%
Enterprise Value	50.03M	PEG	-	EPS next Q	-0.90	Inst Own	12.76%	Short Float	7.66%	Perf Quarter	-31.60%
Income	-57.31M	P/S	-	EPS this Y	69.24%	Inst Trans	8.57%	Short Ratio	2.60	Perf Half Y	-49.49%
Sales	0.00M	P/B	1.35	EPS next Y	42.43%	ROA	-59.25%	Short Interest	0.61M	Perf YTD	-43.87%
Book/sh	1.46	P/C	1.52	EPS next 5Y	34.18%	ROE	-116.63%	52W High	16.94 -88.37%	Perf Year	-36.45%
Cash/sh	1.30	P/FCF	-	EPS past 3/5Y	60.13% -	ROIC	-87.51%	52W Low	1.52 29.60%	Perf 3Y	-90.30%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.22% 12.16%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	24.83%	Oper. Margin	-	ATR (14)	0.27	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.22	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	34.02	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.22	EPS Q/Q	46.81%	SMA20	-12.15%	Beta	2.09	Target Price	13.50
Payout	-	Debt/Eq	0.86	Sales Q/Q	-	SMA50	-30.29%	Rel Volume	25.77	Prev Close	2.13
Employees	34	LT Debt/Eq	0.73	Earnings	May 06 AMC	SMA200	-40.83%	Avg Volume	234.85K	Price	1.97
IPO	May 26, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-151.79% -100.00%	Trades		Volume	6,052,585	Change	-7.51%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-06-25	Initiated	Laidlaw	Buy	$5
Oct-07-22	Initiated	Morgan Stanley	Equal-Weight	$7.50

Jun-30-25 09:15AM	Senti Bio Participates in Nasdaq Amplify Spotlight Series (GlobeNewswire)
Jun-24-25 08:45AM	Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference (GlobeNewswire)
Jun-18-25 07:00AM	Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia (GlobeNewswire) -17.99%
Jun-09-25 04:30PM	Senti Biosciences Announces New Employment Inducement Grants (GlobeNewswire) -18.75%
Jun-06-25 09:05AM	Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC (GlobeNewswire) +7.87%
04:05PM	Loading…
May-22-25 04:05PM	Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar (GlobeNewswire) -5.28%
08:30AM	Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202 (GlobeNewswire)
May-08-25 08:35AM	Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 (GlobeNewswire)
May-06-25 04:35PM	Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development (GlobeNewswire)
May-01-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
09:15AM	Senti Bio Releases Virtual Investor "What This Means" Segment (GlobeNewswire)
Apr-30-25 09:00AM	Senti Bio to Present at the Citizens JMP Life Sciences Conference (GlobeNewswire)
Apr-28-25 07:00AM	Senti Bio's SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML (GlobeNewswire) -27.20%
Apr-24-25 08:35AM	Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 on Monday, April 28th at 8:30 AM ET (GlobeNewswire) +9.93%
Apr-21-25 09:05AM	Senti Bio Participates in a Virtual Investor KOL Connect Segment (GlobeNewswire)
09:15AM	Loading…
Apr-16-25 09:15AM	Senti Bio (NASDAQ: SNTI) to Participate in a Live Virtual Investor Closing Bell Segment (GlobeNewswire)
Apr-10-25 08:45AM	Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D. (GlobeNewswire) -7.99%
Apr-07-25 08:45AM	Senti Bio Joins Webull Corporate Connect Service Platform (GlobeNewswire)
Apr-03-25 09:00AM	Senti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire) -6.54%
Mar-20-25 04:01PM	Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights (GlobeNewswire)
Mar-13-25 04:01PM	Senti Bio Appoints Feng Hsiung to Board of Directors (GlobeNewswire) +8.72%
Feb-25-25 08:00AM	Senti Bio Strengthens Leadership Team with Strategic Hires (GlobeNewswire)
Jan-06-25 09:00AM	Senti Bio Announces Additional $11.5 Million of Financing (GlobeNewswire) +5.35%
Dec-16-24 08:00AM	Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics (GlobeNewswire) -8.26%
Dec-05-24 07:00AM	Senti Bio price target raised to $12 from $10 at Chardan (TipRanks) -6.20%
Dec-03-24 08:00PM	Senti Biosciences Announces New Employment Inducement Grants (GlobeNewswire) -28.60% -7.42%
07:18AM	Senti Bio reports positive initial clinical data from Phase 1 trial of SENTI-202 (TipRanks)
Dec-02-24 11:44AM	Why Is Senti Biosciences Stock Surging Over 400% On Monday? (Benzinga) +362.96%
07:10AM	Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing (GlobeNewswire)
07:02AM	Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML (GlobeNewswire)
07:00AM	Loading…
07:00AM	Senti Bio Appoints Fran Schulz to Board of Directors (GlobeNewswire)
Nov-14-24 04:05PM	Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights (GlobeNewswire) -7.73%
Sep-03-24 08:15AM	Senti Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-13-24 04:05PM	Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights (GlobeNewswire) +10.67% +10.15%
Aug-05-24 08:05AM	Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202 (GlobeNewswire) -13.11%
Jul-16-24 08:30AM	Senti Bio Announces Reverse Stock Split (GlobeNewswire)
Jul-02-24 07:40AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) -6.59%
Jul-01-24 08:05AM	Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy (GlobeNewswire) +51.27%
Jun-25-24 08:03AM	Why Is Senti Biosciences (SNTI) Stock Up 32% Today? (InvestorPlace) +11.90%
07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
May-13-24 08:15AM	Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia (GlobeNewswire)
May-09-24 10:55PM	SNTI Stock Earnings: Senti Biosciences Reported Results for Q1 2024 (InvestorPlace) -7.43%
04:05PM	Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights (GlobeNewswire)
Apr-30-24 08:05AM	Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML) (GlobeNewswire) +16.24%
Mar-21-24 10:53PM	SNTI Stock Earnings: Senti Biosciences Misses EPS for Q4 2023 (InvestorPlace) +6.82% -6.64%
04:05PM	Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights (GlobeNewswire)
Jan-05-24 04:05PM	Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program (GlobeNewswire) -6.15% -6.07%
Dec-26-23 11:32AM	Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate (Zacks) +5.48%
Dec-22-23 12:12PM	Why Is Blood Cancer Focused Senti Biosciences Stock Trading Higher Today? (Benzinga) +18.45%
06:30AM	Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia (GlobeNewswire)
Nov-13-23 04:15PM	Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates (GlobeNewswire) -16.31% -19.26%
Nov-07-23 07:54AM	Why Is Senti Biosciences (SNTI) Stock Up 140% Today? (InvestorPlace) +78.08%
Nov-06-23 04:05PM	Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China (GlobeNewswire)
Oct-31-23 09:06AM	Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Sep-27-23 09:05AM	Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting (GlobeNewswire)
Sep-26-23 04:05PM	Senti Bio to Participate in Upcoming Conferences (GlobeNewswire)
Sep-05-23 08:30AM	Senti Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-11-23 09:50AM	Senti Biosciences, Inc. (SNTI) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
08:35AM	Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates (GlobeNewswire)
Aug-10-23 08:35AM	Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners (GlobeNewswire)
Jun-05-23 08:04AM	Here's Why Senti Biosciences (NASDAQ:SNTI) Must Use Its Cash Wisely (Simply Wall St.)
May-20-23 08:05AM	Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting (GlobeNewswire)
May-09-23 04:05PM	Senti Bio Announces First Quarter 2023 Results and Pipeline Updates (GlobeNewswire) -8.00%
May-02-23 04:45PM	Senti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual Meeting (GlobeNewswire)
Apr-17-23 08:45AM	Senti Bio Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs at Annual AACR Meeting (GlobeNewswire) -6.54%
Apr-14-23 09:00AM	Senti Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-22-23 05:09PM	Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights (GlobeNewswire)
Mar-14-23 04:35PM	Senti Bio Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR Meeting (GlobeNewswire) -8.63%
Feb-06-23 06:26AM	Investors in Senti Biosciences (NASDAQ:SNTI) have unfortunately lost 82% over the last year (Simply Wall St.)
Feb-03-23 04:05PM	Senti Biosciences Announces New Employment Inducement Grants (GlobeNewswire)
Feb-01-23 04:05PM	Senti Bio to Present at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-27-23 08:00AM	Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance (GlobeNewswire)
Dec-27-22 06:53AM	We Think Senti Biosciences (NASDAQ:SNTI) Needs To Drive Business Growth Carefully (Simply Wall St.) -6.72%
Dec-19-22 07:55AM	Senti Bio to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.23%
Dec-11-22 09:00AM	Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event (GlobeNewswire)
Nov-23-22 07:55AM	Senti Bio to Host Investor Event Highlighting SENTI-202 at the 2022 ASH Annual Meeting (GlobeNewswire) +6.16%
Nov-16-22 06:16AM	Senti Biosciences Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-10-22 07:55AM	Senti Bio Reports Third Quarter Financial Results and Pipeline Updates (GlobeNewswire) +8.30%
Nov-03-22 09:05AM	Senti Bio to Present Preclinical Data for SENTI-202 at the 2022 ASH Annual Meeting (GlobeNewswire) +7.14%
Oct-28-22 04:05PM	Senti Bio Announces New Employment Inducement Grants (GlobeNewswire)
Oct-05-22 08:01AM	Senti Bio to Present Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at SITC Annual Meeting (GlobeNewswire)
Oct-04-22 07:04AM	Positive week for Senti Biosciences, Inc. (NASDAQ:SNTI) institutional investors who lost 75% over the past year (Simply Wall St.) +105.60%
Sep-20-22 04:02PM	Senti Bio to Participate in Chardans 6th Annual Genetic Medicines Conference (GlobeNewswire) -7.32%
Sep-06-22 04:01PM	Senti Bio to Present at Morgan Stanley 20th Annual Global Healthcare Conference (GlobeNewswire)
Sep-01-22 11:57AM	Chardan Announces Launch of ChEF (Chardan Equity Facility) (PR Newswire)
Aug-19-22 04:05PM	Senti Biosciences Announces New Employment Inducement Grants (GlobeNewswire) +5.21%
Aug-15-22 04:05PM	Senti Bio Reports Second Quarter Financial Results and Business Updates (GlobeNewswire)
Jul-30-22 09:13AM	Senti Biosciences (NASDAQ:SNTI) shareholders are up 68% this past week, but still in the red over the last year (Simply Wall St.)
Jul-01-22 10:39AM	Bay Area's stream of new public companies has slowed to a weak trickle (American City Business Journals)
Jun-13-22 12:55PM	Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Deliver On Growth Plans? (Simply Wall St.) -45.00%

Senti Biosciences, Inc. is a biotechnology company. It engages in the business of developing next-generation cell and gene therapies engineered with a gene circuit platform technology to fight challenging diseases. The company was founded by Timothy K. Lu, Wilson Wong, and Philip Lee on June 9, 2016 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lu Timothy K	CEO	Feb 04 '25	Sale	4.07	3,922	15,963	82,627	Feb 06 08:23 PM
Lu Timothy K	CEO	Feb 06 '25	Sale	4.36	545	2,376	82,082	Feb 06 08:23 PM
Rajangam Kanya	Pres. & Chief Med. & Dev. Off.	Feb 04 '25	Sale	4.07	1,297	5,279	8,803	Feb 06 07:53 PM
Rajangam Kanya	Pres. & Chief Med. & Dev. Off.	Feb 06 '25	Sale	4.37	182	795	8,621	Feb 06 07:53 PM
Omid C Farokhzad	Former Affiliate	Dec 02 '24	Proposed Sale	2.16	83,277	179,878		Dec 02 04:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SNTI

Senti Biosciences Inc

Upgrade your FINVIZ experience